Skip to main content

Cisplatin-Induced Senescence and Growth Inhibition in Human Non-Small Cell Lung Cancer Cells With Ectopic Transfer of p16I NK4a

Buy Article:

$79.00 plus tax (Refund Policy)

Abstract:

DNA damage is lethal and capable of inducing cellular aging or apoptosis. In this work, the highly tumorigenic and cisplatin-resistant human non-small cell lung cancer (NSCLC) cells were transfected with construct encoding the complete sequence of p16INK4a (p16). The stable clones with elevated p16 exhibited enhanced sensitivities to low concentration cisplatin treatment. Further study indicated that cisplatin arrested cells at G2/M phase and the effectiveness is proportional to the level of p16 expressed. The growth of the xenograft tumors established by p16 transfectants in nude mice was also suppressed by cisplatin by inducing senescence-like phenotype. The data altogether indicated that, in cisplatin-resistant tumor cells with basal endogenous p16, the growth suppression by drugs can be greatly improved by ectopic gene transfer.

Keywords: Cisplatin; Human non-small cell lung cancer cells; p16INK4a

Document Type: Research Article

DOI: https://doi.org/10.3727/096504007783338331

Affiliations: 1: Department of Life Science, National Taiwan Normal University, Taipei, Taiwan, Republic of China 2: Department of Life Science, National Taiwan Normal University, Taipei, Taiwan, Republic of China, Department of Biotechnology, Kaoshiung Medical University, Kaoshiung, Taiwan, Republic of China

Publication date: 2007-10-01

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more